Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy.
Hessling K, Brand C, Schwöppe C, Gerwing M, Pavelka S, Berdel AF, Hintelmann H, Hamacher R, Müller-Tidow C, Egerer G, Hartmann W, Grünewald I, Lindner LH, Di Gioia D, Hecker JS, Maurer S, Pink D, Fried M, Zapata Bonilla SA, Scheuble AM, Lordick F, Ivanyi P, Fobker M, Lenz G, Gerss J, Kessler T, Berdel WE, Schliemann C.
Hessling K, et al. Among authors: gerss j.
Sci Rep. 2026 Feb 19;16(1):7389. doi: 10.1038/s41598-026-40362-4.
Sci Rep. 2026.
PMID: 41714802
Free PMC article.
Clinical Trial.